A Study of Pregnancy and Pregnancy Outcomes in Women With Breast Cancer Treated With Trastuzumab, Pertuzumab in Combination With Trastuzumab, or Ado-Trastuzumab Emtansine



Status:Recruiting
Conditions:Breast Cancer, Cancer, Women's Studies
Therapuetic Areas:Oncology, Reproductive
Healthy:No
Age Range:18 - Any
Updated:4/5/2019
Start Date:January 14, 2009
End Date:January 31, 2025
Contact:MotHER Registry Coordinating Center www.motherpregnancyregistry.com
Phone:800-690-6720

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria

An Observational Study of Pregnancy and Pregnancy Outcomes in Women With Breast Cancer Treated With Herceptin, Perjeta in Combination With Herceptin, or Kadcyla During Pregnancy or Within 7 Months Prior to Conception

The MotHER Pregnancy Registry is a United States (U.S.)-based, prospective, observational
cohort study in women with breast cancer who have been or are being treated with a
trastuzumab (herceptin)-containing regimen with or without pertuzumab (perjeta) or
ado-trastuzumab emtansine (kadcyla) during pregnancy or within 7 months prior to conception
(regardless of cancer stage at the time of trastuzumab, pertuzumab, or ado-trastuzumab
emtansine exposure).


Inclusion Criteria:

- Pregnant; women identified at any trimester of pregnancy may enroll in this study as
long as enrollment occurs prior to experiencing pregnancy outcome (that is [i.e.],
live birth, stillbirth, or abortion)

- Exposure to at least one dose of trastuzumab (as adjuvant or metastatic treatment),
pertuzumab plus trastuzumab combination treatment, or ado-trastuzumab emtansine during
pregnancy or within 7 months prior to conception

- United States resident

Exclusion Criteria:

- Prior knowledge of pregnancy outcome (i.e., live birth, stillbirth, or abortion) at
time of enrollment
We found this trial at
1
site
Kendle International Inc.
Wilmington, North Carolina 28405
?
mi
from
Wilmington, NC
Click here to add this to my saved trials